Trial Profile
Alternate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer Neoadjuvant Treatment (ALTERNATE) in Postmenopausal Women: A Phase III Study
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 17 May 2022
Price :
$35
*
At a glance
- Drugs Anastrozole (Primary) ; Fulvestrant (Primary)
- Indications Advanced breast cancer; Early breast cancer; HER2 negative breast cancer
- Focus Therapeutic Use
- Acronyms ALTERNATE
- 13 Apr 2022 Results assessing effect of intrinsic subtype on inhibition of tumor growth by anastrozole vs. fulvestrant vs. the combination presented at the 113th Annual Meeting of the American Association for Cancer Research
- 11 Dec 2020 Results presented at the 43rd Annual San Antonio Breast Cancer Symposium
- 12 Jun 2020 Planned primary completion date changed from 1 Aug 2025 to 31 Aug 2025.